Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$9.47
-2.8%
$9.17
$6.00
$11.22
$2.41B0.555.22 million shs4.59 million shs
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$38.49
+0.8%
$33.18
$19.72
$40.30
$3.02B0.9958,990 shs222,305 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.22
-0.4%
$1.35
$0.98
$1.61
$917.44M1.482.75 million shs1.14 million shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$28.65
-0.5%
$21.24
$12.21
$44.60
$1.80B-0.96856,269 shs280,859 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-1.72%-11.37%+11.95%+3.18%+8.71%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-0.93%-4.41%+22.07%+12.70%+63.40%
OPKO Health, Inc. stock logo
OPK
OPKO Health
-0.81%-18.12%-14.08%+3.39%-8.96%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
+3.23%+3.97%+45.35%+36.72%+124.49%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$9.47
-2.8%
$9.17
$6.00
$11.22
$2.41B0.555.22 million shs4.59 million shs
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$38.49
+0.8%
$33.18
$19.72
$40.30
$3.02B0.9958,990 shs222,305 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.22
-0.4%
$1.35
$0.98
$1.61
$917.44M1.482.75 million shs1.14 million shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$28.65
-0.5%
$21.24
$12.21
$44.60
$1.80B-0.96856,269 shs280,859 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-1.72%-11.37%+11.95%+3.18%+8.71%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-0.93%-4.41%+22.07%+12.70%+63.40%
OPKO Health, Inc. stock logo
OPK
OPKO Health
-0.81%-18.12%-14.08%+3.39%-8.96%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
+3.23%+3.97%+45.35%+36.72%+124.49%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
2.67
Moderate Buy$20.80119.53% Upside
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.82
Moderate Buy$49.3028.65% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
1.80
Reduce$1.5526.53% Upside
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
2.56
Moderate Buy$44.2958.20% Upside

Current Analyst Ratings Breakdown

Latest OPK, CLDX, BCRX, and ZBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/13/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Initiated CoverageNeutral$12.00
7/9/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
DowngradeSell (D-)Sell (E+)
7/7/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Boost Price TargetOutperform$13.00 ➝ $14.00
6/30/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Reiterated RatingBuy$32.00
6/30/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Boost Price TargetOverweight$27.00 ➝ $29.00
6/24/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Reiterated RatingSell (D-)
6/15/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Reiterated RatingBuy$42.00
6/10/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Boost Price TargetBuy$38.00 ➝ $45.00
6/3/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Reiterated RatingBuy
6/3/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Reiterated RatingBuy
6/1/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Reiterated RatingHold (C)
(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$874.84M2.75$1.18 per share8.00($0.57) per share-16.62
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$1.54M1,953.08N/AN/A$7.93 per share4.83
OPKO Health, Inc. stock logo
OPK
OPKO Health
$581.12M1.59N/AN/A$1.67 per share0.73
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$10M176.73N/AN/A$4.51 per share6.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$263.86M-$1.78N/A20.16N/A-51.71%-76.36%60.12%8/3/2026 (Estimated)
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$225.68M-$0.27N/AN/AN/A-36.63%-16.78%-10.98%7/30/2026 (Estimated)
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$377.74M-$8.47N/AN/AN/AN/A-99.99%-58.06%8/11/2026 (Estimated)

Latest OPK, CLDX, BCRX, and ZBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$0.89N/AN/AN/A$15.00 millionN/A
8/6/2026Q2 2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$1.04N/AN/AN/A$0.74 millionN/A
8/3/2026Q2 2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$0.14N/AN/AN/A$183.28 millionN/A
7/30/2026Q2 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.08N/AN/AN/A$131.23 millionN/A
5/13/2026Q1 2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.4742-$1.46+$0.0142-$1.46$25.00 millionN/A
5/7/2026Q1 2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million
5/6/2026Q1 2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million
4/28/2026Q1 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.07N/A-$0.07$130.51 million$124.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/AN/AN/AN/AN/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/A
1.91
1.88
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
8.92
8.92
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.28
3.61
3.17
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1.04
11.94
11.94

Institutional Ownership

CompanyInstitutional Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
85.88%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A

Insider Ownership

CompanyInsider Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
3.80%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
5.20%
OPKO Health, Inc. stock logo
OPK
OPKO Health
44.72%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
22.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
530254.16 million244.51 millionOptionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
15078.49 million74.41 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
1,373755.09 million417.42 millionOptionable
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A63.13 million49.24 millionN/A

Recent News About These Companies

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 8% - Should You Sell?
Zenas BioPharma Inc ZBIO
Zenas Biopharma Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCryst Pharmaceuticals stock logo

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.46 -0.28 (-2.82%)
As of 02:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Celldex Therapeutics stock logo

Celldex Therapeutics NASDAQ:CLDX

$38.49 +0.32 (+0.84%)
As of 02:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.22 -0.01 (-0.41%)
As of 02:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Zenas BioPharma stock logo

Zenas BioPharma NASDAQ:ZBIO

$28.65 -0.13 (-0.46%)
As of 02:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.